At InSphero, we offer industry-leading in vitro DILI testing that enables early identification of highly toxic compounds through a physiologically relevant liver model compatible with high-throughput screening. Our 3D InSight™ Liver Microtissues support a broad range of therapeutic modalities, including small molecules and antisense oligonucleotides (ASOs).
In contrast to conventional 2D hepatocyte models with limited predictive performance, or complex microfluidic systems that are costly and low throughput, the 3D InSight™ Liver Microtissues provide a physiologically representative, scalable, and cost-efficient platform with rapid turnaround times. This approach is widely adopted and trusted by leading companies in the field.
Drug candidates can be submitted directly for testing, and we deliver a comprehensive, decision-ready report with actionable insights to support the development of safer and more effective therapies. With an extensive publication record, including studies evaluating hundreds of FDA-approved drugs, this platform enables more confident and timely go/no-go decisions throughout the discovery and development pipeline.
Improve confidence in your early DILI risk decisions.
See how 3D InSight™ in vitro DILI testing, benchmarked with 152 FDA-approved drugs and able to flag 8/10 withdrawn drugs, can support safer drug candidate selection.
We help you overcome the challenges of DILI with a screening solution that de-risks your pipeline early and accelerate time to market.
Achieve accurate DILI predictions with 3D InSight™ Liver Microtissues , physiologically relevant co-culture liver models composed of primary hepatocytes and non-parenchymal liver cells from human or preclinical species.
With four weeks of sustained viability and functionality, these models closely mimic in vivo liver physiology, enabling early and thorough evaluation of your drug candidates’ toxicity.
Accelerate your drug discovery with our standardized and high-throughput cytotoxicity DILI assay. We offer weekly human and monthly animal DILI testing, evaluating 7 concentrations of your compound in 4 biological replicates over 7 or 14 days.
You’ll receive a comprehensive analysis report within 10 working days after treatment, streamlining fast decision-making and keeping your projects moving forward.
Make confident go/no-go decisions with reference data from hundreds of FDA-approved drugs. We continuously screen compounds using our standardized DILI assays and publish the results in leading scientific journals, building a comprehensive database to benchmark your findings.
Customize your DILI assessment by multiplexing your testing with an extensive portfolio of optional biomarkers, supernatant collection, and flexible treatment regimens lasting up to 28 days, ensuring the data you receive is precisely tailored to your program’s unique needs.
Standardized testing that delivers high-quality, reproducible, and actionable data, supported by a large dataset of FDA-approved drugs, enabling you to make confident go/no-go decisions, de-risk your development programs, and bring safer drugs to market faster.
Our standardized assay includes
DILI Flag / DILI Flag Plus: Accelerate hit-to-lead development with our high-throughput early screening assay for rapid detection and flagging of highly cytotoxic compounds.
DILI / DILI Plus: Accelerate lead optimization phases by rank ordering the cytotoxicity of your lead compounds and benchmark drug candidates against the published peer-reviewed DILI reference database.
Extend your safety assessment beyond liver with our standardized DIGIT & DIGIT Plus gastrointestinal toxicity assays using patient-derived intestinal organoids.
Getting started with our DILI testing service is fast and easy. Choose the solution that best fits your program, ship your compounds with ease, and let our experts handle the rest. You’ll receive high-quality, actionable data in a comprehensive report designed to support confident decision-making.
From early-stage DILI hazard identification to advanced multi-parametric readouts, choose a solution aligned with your discovery or preclinical strategy.
Ship your drug candidates with ease. We coordinate logistics and prepare 3D liver microtissues in parallel to keep timelines on track.
Our scientific team executes your study with optimized dosing strategies, validated workflows, and robust readouts for high-confidence results.
Receive a detailed, publication-grade report with actionable insights designed to support internal reviews, regulatory submissions, and portfolio decisions.
Fill in form below to contact our 3D in vitro experts
Get the latest news on 3D in vitro research
Fill in the form below to view this resource
